Investigational Drug Shows Positive Results for MASH Treatment in Phase 2 Trial

A Phase 2 clinical trial for zabopegdutide, a GLP-1/glucagon agonist, demonstrated significant efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH). The study reported that 62.5% of patients achieved MASH resolution without worsening fibrosis after 48 weeks, a substantial improvement compared to placebo. These findings suggest a promising new therapeutic option for a condition with unmet medical needs.